The present invention provides a process for the recovery and/or purification of a recombinantly expressed intracellular protein comprising the sequence of Annexin A5 (AnxA5) from an endotoxin-producing host cell with a cell wall, wherein the process comprises releasing the intracellular protein from the host cell, characterised in that the step of releasing the intracellular AnxA5 protein is conducted in the presence of a homogenisation buffer comprising non-ionic detergent, and preferably wherein the process does not include any centrifugation steps for the recovery and/or purification of the AnxA5 protein after its release from the host cell and/or in which the AnxA5 protein remains in solution throughout the process except when temporarily bound to any chromatographic resins.

The present disclosure relates to polypeptides and polypeptide analogues derived from Annexin A1 as well as compositions comprising said polypeptides or polypeptide analogues for treatment of inflammatory and ischemic conditions.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

Described herein in aspects is annexin A5 for interacting with angiotensin converting enzyme 2 (ACE2) and/or for preventing and/or treating a coronavirus infection. Also described is a method for preventing and/or treating an ACE2-mediated infection and/or a coronavirus infection, the method comprising administering annexin A5 to a subject in need thereof.

A method, composition, and kit for treating a malarial infection in a subject by using an enzyme conjugate comprising a variant cystathione-gamma-lyase and a targeting ligand which binds to erythrocytes infected with Plasmodium pathogens. The variant cystathione-gamma-lyase has methioninase activity. Also disclosed is a method of treating Plasmodium-infected blood by exposing the infected blood with the enzyme conjugate.

Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.

A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.

A method, composition, and kit for treating a malarial infection in a subject by using an enzyme conjugate comprising a variant cystathione-gamma-lyase and a targeting ligand which binds to erythrocytes infected with Plasmodium pathogens. The variant cystathione-gamma-lyase has methioninase activity. Also disclosed is a method of treating Plasmodium-infected blood by exposing the infected blood with the enzyme conjugate.

The present invention relates to fusion proteins which are capable of binding to phosphatidylserine comprising a phosphatidylserene binding ligand and a modified O6-alkylguanine-DNA alkyltransferase which is capable of autoconjugation to an O6-benzylguanine-modified label, the fusion proteins being capable of binding to phosphatidylserine on the surface of a cell undergoing apoptosis. The invention also relates to recombinant polypeptide precursors of the fusion proteins which comprise a secretion leader sequence, purification tag, protease cleavage site and the fusion protein. Also included in the scope of the invention are nucleic acids encoding the recombinant polypeptide precursor, vectors comprising the nucleic acids, host cells comprising the vectors, methods of production of the fusion proteins, kits and assays for detecting apoptosis.

Aspects of the disclosure include materials and methods for the targeted delivery of growth factors, and other compounds that stimulate bone growth and in some aspect bone healing. Some aspects of the disclosure include methods for synthesizing and testing these compounds. Some aspects of the invention include methods of using the compounds disclosed herein to treat bone fractures and bone defects.